Shots: The EC has approved Xofluza (baloxavir marboxil) for uncomplicated influenza in patients aged≥12yrs. Additionally, the EC has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged≥12yrs. The approval […]readmore
Tags : BLOCKSTONE
Shots: The P-III MINISTONE-2 involves assessing of Xofluza vs oseltamivir in children with influenza infection & showing influenza symptoms aged 1 to <12yrs., resulted in meeting its 1EPs i.e, patients […]readmore
Shots: The P-III BLOCKSTONE study results involves assessing of Xofluza vs PBO in children & adults diagnosed with influenza, confirmed by rapid influenza diagnostic test in Japan The P-III BLOCKSTONE […]readmore